PuSH - Publikationsserver des Helmholtz Zentrums München

Tschöp-Lechner, K. ; Drexler, I. ; Hammer, D. ; Neumann, D. ; Pohla, H. ; Sutter, G.* ; Nößner, E. ; Issels, R.D.

Modified vaccinia virus Ankara delivers a robust surrogate marker for immune monitoring to sarcoma cells even if cells are being exposed to chemotherapy and heat treatment.

Int. J. Hyperthermia 28, 33-42 (2012)
DOI PMC
Open Access Gold möglich sobald Verlagsversion bei der ZB eingereicht worden ist.
Purpose: Adding hyperthermia to chemotherapy improved the clinical outcome of patients with high risk soft tissue sarcoma. Further improvement might be possible if combined with vaccination strategies. As no sarcoma-associated antigens are known, the ecto
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
Schlagwörter Hyperthermia ; Immune Monitoring ; Mva ; Sarcoma ; Tumour Vaccine; CYTOTOXIC T-CELLS; MELANOMA-ASSOCIATED ANTIGEN; AUTOLOGOUS TUMOR-CELLS; DENDRITIC CELLS; IN-VITRO; METASTATIC MELANOMA; HUMAN TYROSINASE; TRIAL; HYPERTHERMIA; VACCINATION
ISSN (print) / ISBN 0265-6736
e-ISSN 1464-5157
Zeitschrift International Journal of Hyperthermia
Quellenangaben Band: 28, Heft: 1, Seiten: 33-42 Artikelnummer: , Supplement: ,
Verlag Informa Healthcare
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Molecular Immunology (IMI)
Institute of Virology (VIRO)
CCG Tumor Therapy with Hyperthermia (IMI-KTH)